source
- FDA CDER chief says expanding generic GLP-1 drugs is top priority to cut American costsMichael Davis, director of the FDA's Center for Drug Evaluation and Research, highlighted that increasing the supply of generic GLP-1 medicines is a key focus for the agency. He noted that broader…
- Operational talent, not just science, will drive next biopharma breakthroughsThe piece points out that while breakthrough science, founders and venture funding are typical markers of progress, the real test is moving a promising therapy through GMP production, quality syste…